These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 31264948)

  • 1. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
    McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
    Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
    Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
    Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
    Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
    Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of immediate gadolinium contrast media reactions.
    Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
    Aran S; Shaqdan KW; Abujudeh HH
    Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children.
    Forbes-Amrhein MM; Dillman JR; Trout AT; Koch BL; Dickerson JM; Giordano RM; Towbin AJ
    Invest Radiol; 2018 May; 53(5):313-318. PubMed ID: 29337841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.
    Kramer JH; Arnoldi E; François CJ; Wentland AL; Nikolaou K; Wintersperger BJ; Grist TM
    Invest Radiol; 2013 Mar; 48(3):121-8. PubMed ID: 23211552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents.
    Strzeminska I; Factor C; Robert P; Grindel AL; Comby PO; Szpunar J; Corot C; Lobinski R
    Invest Radiol; 2020 Mar; 55(3):138-143. PubMed ID: 31917763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Reactions to Gadolinium-Based Contrast Agents in a Pediatric Cohort: A Retrospective Study of 16,237 Injections.
    McDonald JS; Larson NB; Kolbe AB; Hunt CH; Schmitz JJ; Kallmes DF; McDonald RJ
    AJR Am J Roentgenol; 2021 May; 216(5):1363-1369. PubMed ID: 32755216
    [No Abstract]   [Full Text] [Related]  

  • 11. Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide.
    Ramalho J; Semelka RC; AlObaidy M; Ramalho M; Nunes RH; Castillo M
    Eur Radiol; 2016 Nov; 26(11):4080-4088. PubMed ID: 26911888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
    Abujudeh HH; Kosaraju VK; Kaewlai R
    AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
    Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
    Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.
    Colosimo C; Ruscalleda J; Korves M; La Ferla R; Wool C; Pianezzola P; Kirchin MA
    Invest Radiol; 2001 Feb; 36(2):72-81. PubMed ID: 11224754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium Deposition in the Brain in a Large Animal Model: Comparison of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Radbruch A; Richter H; Fingerhut S; Martin LF; Xia A; Henze N; Paulus W; Sperling M; Karst U; Jeibmann A
    Invest Radiol; 2019 Sep; 54(9):531-536. PubMed ID: 31261291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats.
    Robert P; Violas X; Grand S; Lehericy S; Idée JM; Ballet S; Corot C
    Invest Radiol; 2016 Feb; 51(2):73-82. PubMed ID: 26606549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
    JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
    Runge VM; Armstrong MR; Barr RG; Berger BL; Czervionke LF; Gonzalez CF; Halford HH; Kanal E; Kuhn MJ; Levin JM; Low RN; Tanenbaum LN; Wang AM; Wong W; Yuh WT; Zoarski GH
    Invest Radiol; 2001 Feb; 36(2):65-71. PubMed ID: 11224753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
    Semelka RC; Hernandes Mde A; Stallings CG; Castillo M
    Magn Reson Imaging; 2013 Jan; 31(1):96-101. PubMed ID: 22898688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.